Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HLCS | P50747 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325805 | 0.98 | CYP1A2 (0.38) | CYP1A2EPHX1DAGLAALDH1A1L3MBTL1 | |
| SCHEMBL6325303 | 0.93 | NFKB1 (0.33) | CYP1A2ALDH1A1 | |
| SCHEMBL6324122 | 0.87 | CYP1A2 (0.48) | CYP1A2EPHX1ALDH1A1L3MBTL1PPARG | |
| SCHEMBL6325530 | 0.87 | CYP1A2 (0.48) | CYP1A2EPHX1ALDH1A1L3MBTL1PPARG | |
| SCHEMBL6332026 | 0.87 | CYP1A2 (0.48) | CYP1A2EPHX1ALDH1A1L3MBTL1PPARG | |
| SCHEMBL6327963 | 0.86 | CYP1A2 (0.40) | CYP1A2EPHX1DAGLAALDH1A1L3MBTL1 | |
| SCHEMBL6326280 | 0.85 | CYP1A2 (0.47) | CYP1A2EPHX1ALDH1A1L3MBTL1PPARG | |
| SCHEMBL6325406 | 0.85 | CYP1A2 (0.47) | CYP1A2EPHX1ALDH1A1L3MBTL1PPARG | |
| SCHEMBL6332614 | 0.85 | CYP1A2 (0.46) | CYP1A2EPHX1ALDH1A1L3MBTL1PPARG | |
| SCHEMBL6325069 | 0.84 | CYP1A2 (0.38) | CYP1A2EPHX1DAGLAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | ZEON CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1420005-A1 | CYCLOPENTANONE DERIVATIVE | Zeon Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009928-A1 | Cyclopentanone derivative | PTGIS, CYP51A1, TRPA1 | CYP1A2 57/4885EPHX1 1386/4885DAGLA 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.